Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau - PubMed
- ️Wed Jan 01 1997
Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau
A D Alonso et al. Proc Natl Acad Sci U S A. 1997.
Abstract
The microtubule-associated protein (MAP) tau is abnormally hyperphosphorylated in Alzheimer disease and accumulates in neurons undergoing neurofibrillary degeneration. In the present study, the associations of the Alzheimer-hyperphosphorylated tau (AD P-tau) with the high molecular weight MAPs (HMW-MAPs) MAP1 and MAP2 were investigated. The AD P-tau was found to aggregate with MAP1 and MAP2 in solution. The association of AD P-tau to the MAPs resulted in inhibition of MAP-promoted microtubule assembly. However, unlike the coaggregation of AD P-tau and normal tau, the association between AD P-tau and the HMW-MAPs did not result in the formation of filaments/tangles. The affinity of the tau-AD P-tau association was higher than that of HMW-MAPs-AD P-tau because normal tau inhibited the latter binding. The association between AD P-tau and the HMW-MAPs also appeared to occur in situ because these proteins cosedimented from the Alzheimer brain extracts, and, in the sediment, the levels of the HMW-MAPs correlated with the levels of AD P-tau. These studies suggested that the abnormally phosphorylated tau can sequester both normal tau and HMW-MAPs and disassemble microtubules but, under physiological conditions, can form tangles of filaments only from tau.
Figures
![Figure 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8945/19321/1641d5d990e1/pq0173313001.gif)
Binding of MAP1 and MAP2 to AD P-tau. The binding of MAP1 and MAP2 to AD P-tau was determined as described using a fixed amount of AD P-tau or normal tau (8 μg in 100 μl) and MAP1 and MAP2 (70 μg/100 μl). The proteins were mixed in 100 mM Mes buffer (pH 6.7) containing 2 mM EGTA, 0.5 mM MgCl2, 2% BSA, 1 μM aprotinin, and 20 μM leupeptin (binding buffer) and were incubated for 30 min at 37°C. Similar incubations were carried out using rat brain cytosol (100 μg protein/100 μl) as the source of tau, MAP1, and MAP2. The incubated samples were overlaid a 100-μl cushion of 8% sucrose in the binding buffer and centrifuged at 100,000 × g for 60 min. As a control, MAP1, MAP2, and brain cytosol mixed with normal tau (8 μg) were processed identically to the mixtures of these proteins with AD P-tau. The amounts of tau, MAP1, MAP2, and tubulin (in the case of cytosolic extract) in the pellet and the supernatant fractions were assayed by radioimmuno-slot blot. AD P-tau bound to all of the MAPs when using both purified proteins and proteins in brain extract. The levels of binding of AD P-tau were within tau > MAP2 > MAP1.
![Figure 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8945/19321/95b4027af4eb/pq0173313002.gif)
Electron micrographs showing the products of association of AD P-tau with tau, MAP1, and MAP2 negatively stained with phosphotungstic acid. MAP1– and MAP2–AD P-tau aggregates were induced as described in Fig. 1. Under identical conditions, 150 μg of normal tau and 8 μg of AD P-tau/100 μl also were incubated. Aliquots of the incubated mixture of MAP1 and AD P-tau (a), MAP1 alone (b), MAP2 and AD P-tau (c), or tau and AD P-tau (d and e) were taken after centrifugation and were examined by negative stain electron microscopy. Association of AD P-tau with only tau and not MAP1 or MAP2 resulted in the formation of filaments/tangles. (Bars = 1 μm for a and d; 0.5 μm for b, c, and e.)
![Figure 3](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8945/19321/f6ace972a00a/pq0173313003.gif)
Relationship of the ratio of HMW-MAPs in the pellet/supernatant to the levels of AD P-tau in the pellet. The levels of MAP1 or MAP2 were determined in the 200,000 × g supernatant (Supt) and the 27,000 to 200,000 × g pellet (Pellet) from brain homogenates of 12 (MAP2) to 13 (MAP1) AD cases (•) and four Huntington disease cases (○). The levels of AD P-tau also were determined in the 27,000 × g to 200,000 × g fraction from the same brains by radioimmuno-slot blot using Tau-1 as the primary antibody (18). The AD P-tau values are expressed as cpm of the 125I secondary antibody used. The Pellet/Supt ratios of the HMW-MAPs were obtained from the means of triplicate assays determined at three different concentrations. The levels of the MAPs correlate directly with the levels of AD P-tau in the 27,000 × g to 200,000 × g pellet, and levels of the HMW-MAPs in the 200,000 × g supernatant correlate inversely with the AD P-tau in the pellet. The Pellet/Supt ratios of the HMW-MAPs show a significant direct correlation with the AD P-tau levels (p < 0.05).
![Figure 4](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8945/19321/6240d176e46e/pq0173313004.gif)
Inhibition of the MAP1- and MAP2-promoted microtubule assembly by AD P-tau. Polymerization of tubulin was determined as described. The assembly reaction was carried out using (i) 1.0 mg/ml MAP1 or a mixture of MAP1 and 2 mg/ml AD P-tau (a) or (ii) 1.0 mg/ml MAP2 or MAP2 plus 2 mg/ml AD P-tau (b). For comparison, the inhibition of tau-promoted microtubule assembly is reproduced (c) from our previous report (5).
![Figure 5](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8945/19321/be976d203d57/pq0173313005.gif)
Electron micrographs showing the products of microtubule assembly with MAP1 and MAP2 and the effect of AD P-tau on the assembly. Microtubule assembly was carried out from rat brain tubulin by the addition of MAP1 (a), MAP2 (b), or MAP2 and AD P-tau (c and d, respectively) as in Fig. 4. Aliquots of the reaction mixture were negatively stained with phosphotungstic acid after 4 (c) or 30 (a, b, and d) min of incubation. Only an occasional microtubule was seen with tubulin alone (data not shown) and with AD P-tau after 30 min of incubation (d), and a large number of microtubules was observed in the assembly with MAP1 (a), MAP2 (b), and MAP2 with AD P-tau after 4 min of incubation (c). (Bars = 1 μm for a-c and 0.5 μm for d.)
![Figure 6](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8945/19321/7f47f7a4aee7/pq0173313006.gif)
Disruption of the MAP2-promoted microtubules by AD P-tau. The assembly of microtubules was determined turbidimetrically as described. The arrow indicates the time of addition of the AD P-tau (2 mg/ml final concentration) or the same volume of buffer to MAP2-preassembled microtubules. Samples of the reaction mixture were examined by negatively stained electron microscopy. Only an occasional microtubule was seen after 20 min of AD P-tau addition (not shown).
Similar articles
-
Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.
Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, Grundke-Iqbal I. Iqbal K, et al. J Neural Transm Suppl. 1998;53:169-80. doi: 10.1007/978-3-7091-6467-9_15. J Neural Transm Suppl. 1998. PMID: 9700655 Review.
-
Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach.
Iqbal K, Alonso AD, Gondal JA, Gong CX, Haque N, Khatoon S, Sengupta A, Wang JZ, Grundke-Iqbal I. Iqbal K, et al. J Neural Transm Suppl. 2000;59:213-22. doi: 10.1007/978-3-7091-6781-6_22. J Neural Transm Suppl. 2000. PMID: 10961432 Review.
-
Alzheimer neurofibrillary degeneration: therapeutic targets and high-throughput assays.
Iqbal K, Alonso Adel C, El-Akkad E, Gong CX, Haque N, Khatoon S, Pei JJ, Tanimukai H, Tsujio I, Wang JZ, Grundke-Iqba I. Iqbal K, et al. J Mol Neurosci. 2003;20(3):425-9. doi: 10.1385/jmn:20:3:425. J Mol Neurosci. 2003. PMID: 14501027 Review.
-
Iqbal K, Alonso Adel C, El-Akkad E, Gong CX, Haque N, Khatoon S, Pei JJ, Tsujio I, Wang JZ, Grundke-Iqbal I. Iqbal K, et al. J Mol Neurosci. 2002 Aug-Oct;19(1-2):95-9. doi: 10.1007/s12031-002-0017-3. J Mol Neurosci. 2002. PMID: 12212801 Review.
-
Tau in Alzheimer disease and related tauopathies.
Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Iqbal K, et al. Curr Alzheimer Res. 2010 Dec;7(8):656-64. doi: 10.2174/156720510793611592. Curr Alzheimer Res. 2010. PMID: 20678074 Free PMC article. Review.
Cited by
-
Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial.
Iqbal K, Wang X, Blanchard J, Liu F, Gong CX, Grundke-Iqbal I. Iqbal K, et al. Biochem Soc Trans. 2010 Aug;38(4):962-6. doi: 10.1042/BST0380962. Biochem Soc Trans. 2010. PMID: 20658985 Free PMC article. Review.
-
Herskowitz JH, Seyfried NT, Duong DM, Xia Q, Rees HD, Gearing M, Peng J, Lah JJ, Levey AI. Herskowitz JH, et al. J Proteome Res. 2010 Dec 3;9(12):6368-79. doi: 10.1021/pr100666c. Epub 2010 Oct 22. J Proteome Res. 2010. PMID: 20886841 Free PMC article.
-
Tauopathy: A common mechanism for neurodegeneration and brain aging.
Saha P, Sen N. Saha P, et al. Mech Ageing Dev. 2019 Mar;178:72-79. doi: 10.1016/j.mad.2019.01.007. Epub 2019 Jan 19. Mech Ageing Dev. 2019. PMID: 30668956 Free PMC article. Review.
-
Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer's Disease.
Wang HY, Cecon E, Dam J, Pei Z, Jockers R, Burns LH. Wang HY, et al. Int J Mol Sci. 2023 Sep 11;24(18):13927. doi: 10.3390/ijms241813927. Int J Mol Sci. 2023. PMID: 37762230 Free PMC article.
-
Mechanisms of tau-induced neurodegeneration.
Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Iqbal K, et al. Acta Neuropathol. 2009 Jul;118(1):53-69. doi: 10.1007/s00401-009-0486-3. Epub 2009 Jan 30. Acta Neuropathol. 2009. PMID: 19184068 Free PMC article. Review.
References
-
- Iqbal, K., Grundke-Iqbal, I., Zaidi, T., Merz, P. A., Wen, G. Y., Shaikh, S. S., Wisniewski, H. M., Alafuzoff, I. & Wimblad, B. (1986) Lancet ii, 421–426. - PubMed
-
- Grundke-Iqbal I, Iqbal K, Quinlan M, Tung Y-C, Zaidi M S, Wisniewski H M. J Biol Chem. 1986;261:6084–6089. - PubMed
-
- Köpke E, Tung Y-C, Shaikh S, Alonso A del C, Iqbal K, Grundke-Iqbal I. J Biol Chem. 1993;268:24374–24384. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical